Everolimus
Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour
National Cancer Centre, SingaporeSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LBH589 National Cancer Centre, Singapore | Phase 1 | CC |
Same molecule, other indications
Everolimus is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →